Korsana Biosciences, Inc. (KRSA) Balance Sheet
KRSA balance sheet, 2025
December 31, 2025 · U.S. dollars$10.0M assets = $900,000 liabilities + $9.1M equity
Both columns are drawn to the same scale: what KRSA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KRSA financial health
Descriptive bands, not a rating. Fiscal 2025.
KRSA balance sheet trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $5.5M2017 | $10.0M2025 | +7.8%/yr | |
| Total liabilities | $14.0M2017 | $900,0002025 | −29.1%/yr | |
| Shareholders’ equity | −$8.6M2017 | $9.1M2025 | — | |
| Cash & short-term investments | $97.6M2019 | $3.2M2025 | −43.3%/yr | |
| Total debt | $73.9M2019 | $45.7M2020 | −38.1%/yr | |
| Net cash (debt) | $23.7M2019 | $8.7M2020 | −$15.0M | |
| Working capital | −$12.8M2017 | $3.7M2025 | +$16.5M | |
| Current ratio | 0.092017 | 5.152025 | +5.06 | |
| Debt / equity | 0.762019 | 0.772020 | +0.01 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KRSA assets
KRSA liabilities and equity
KRSA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KRSA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $54.4M | $97.6M | — | — |
| Cash & equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $54.4M | $97.6M | — | — |
| Receivables | $1.0M | $556,000 | $0 | $96,000 | $100,000 | $127,000 | $1.5M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $928,000 | $0 | $0 | $0 | $0 |
| Other current assets | $395,000 | $437,000 | $453,000 | $1.3M | $468,000 | $4.0M | $2.1M | $879,000 | $1.3M |
| Total current assets | $4.6M | $4.2M | $8.0M | $14.8M | $55.5M | $58.5M | $101.2M | $879,000 | $1.3M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $1.2M | $1.5M | $50.3M | $79.8M | $6.5M | $4.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $5.3M | $5.3M | $5.3M | $2.0M | $2.4M | $6.6M | $5.5M | $25,000 | $80,000 |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M | $115.4M | $186.5M | $7.4M | $5.5M |
| Liabilities | |||||||||
| Accounts payable | $508,000 | $390,000 | $1.2M | $3.0M | $1.8M | $1.1M | $3.3M | $2.8M | $1.8M |
| Short-term debt | — | — | — | — | — | $6.8M | $3.4M | — | — |
| Total current liabilities | $900,000 | $725,000 | $2.1M | $7.6M | $11.1M | $17.0M | $18.2M | $17.8M | $14.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $176.1M | $10.0M | $0 | $0 | $0 | $38.9M | $70.5M | $0 | $0 |
| Total liabilities | $900,000 | $725,000 | $2.1M | $7.6M | $11.1M | $55.9M | $88.7M | $17.8M | $14.0M |
| Shareholders' equity | |||||||||
| Retained earnings (deficit) | −$271.0M | −$267.5M | −$264.4M | −$259.2M | −$215.1M | −$163.4M | −$85.6M | — | — |
| Accumulated other comprehensive income | — | — | −$12,000 | −$20,000 | −$23,000 | −$27,000 | −$20,000 | −$15.5M | −$15.9M |
| Total shareholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | −$10.4M | −$8.6M |
| Key figures | |||||||||
| Total debt | — | — | — | — | — | $45.7M | $73.9M | — | — |
| Net cash (debt) | — | — | — | — | — | $8.7M | $23.7M | — | — |
| Working capital | $3.7M | $3.5M | $5.9M | $7.2M | $44.4M | $41.5M | $82.9M | −$17.0M | −$12.8M |
| Tangible book value | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | −$10.4M | −$8.6M |
| Current ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 | 0.09 |
| Quick ratio | 4.71 | 5.22 | 3.63 | 1.77 | 4.88 | 3.22 | 5.43 | 0.00 | 0.00 |
| Debt / equity | — | — | — | — | — | 0.77 | 0.76 | — | — |
| Equity / assets | 91.0% | 92.4% | 84.4% | 57.8% | 81.3% | 51.6% | 52.4% | −141.1% | −156.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.4M | $2.8M | $3.2M | $4.6M | $3.0M | $3.6M | $3.2M | $2.9M | $4.6M | $5.7M | $7.6M | $9.1M |
| Cash & equivalents | $1.4M | $2.8M | $3.2M | $4.6M | $3.0M | $3.6M | $3.2M | $2.9M | $4.6M | $5.7M | $7.6M | $9.1M |
| Receivables | $0 | $0 | $1.0M | $100,000 | $525,000 | $581,000 | $556,000 | $44,000 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $123,000 | $266,000 | $395,000 | $397,000 | $489,000 | $277,000 | $437,000 | $632,000 | $127,000 | $318,000 | $453,000 | $756,000 |
| Total current assets | $1.5M | $3.1M | $4.6M | $5.1M | $4.0M | $4.5M | $4.2M | $3.5M | $4.7M | $6.0M | $8.0M | $9.9M |
| Property, plant & equipment (net) | $66,000 | $66,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M | $5.3M |
| Total assets | $6.9M | $8.5M | $10.0M | $10.4M | $9.4M | $9.8M | $9.6M | $8.9M | $10.1M | $11.4M | $13.4M | $15.2M |
| Liabilities | ||||||||||||
| Accounts payable | $1.6M | $457,000 | $508,000 | $480,000 | $462,000 | $483,000 | $390,000 | $304,000 | $651,000 | $741,000 | $1.2M | $814,000 |
| Total current liabilities | $1.8M | $1.7M | $900,000 | $877,000 | $800,000 | $1.1M | $725,000 | $700,000 | $1.3M | $1.4M | $2.1M | $2.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $1.8M | $1.7M | $900,000 | $877,000 | $800,000 | $1.1M | $725,000 | $700,000 | $1.3M | $1.4M | $2.1M | $2.3M |
| Shareholders' equity | ||||||||||||
| Retained earnings (deficit) | −$276.0M | −$274.2M | −$271.0M | −$270.2M | −$269.2M | −$268.9M | −$267.5M | −$268.0M | −$267.3M | −$266.0M | −$264.4M | −$262.7M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | −$16,000 | −$12,000 | −$18,000 |
| Total shareholders' equity | $5.1M | $6.8M | $9.1M | $9.5M | $8.6M | $8.8M | $8.8M | $8.2M | $8.8M | $9.9M | $11.3M | $12.9M |
| Key figures | ||||||||||||
| Working capital | −$329,000 | $1.4M | $3.7M | $4.2M | $3.2M | $3.4M | $3.5M | $2.8M | $3.4M | $4.6M | $5.9M | $7.5M |
| Tangible book value | $5.1M | $6.8M | $9.1M | $9.5M | $8.6M | $8.8M | $8.8M | $8.2M | $8.8M | $9.9M | $11.3M | $12.9M |
| Current ratio | 0.82 | 1.80 | 5.15 | 5.78 | 5.03 | 4.21 | 5.83 | 5.07 | 3.68 | 4.17 | 3.85 | 4.21 |
| Quick ratio | 0.75 | 1.65 | 4.71 | 5.32 | 4.41 | 3.96 | 5.22 | 4.17 | 3.58 | 3.95 | 3.63 | 3.89 |
| Equity / assets | 73.4% | 79.8% | 91.0% | 91.6% | 91.5% | 89.2% | 92.4% | 92.1% | 87.3% | 87.3% | 84.4% | 84.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
KRSA financial position
At the end of fiscal 2025 (December 31, 2025), Korsana Biosciences had total assets of $10.0 million (up 4.3% from a year earlier), total liabilities of $0.9 million and shareholders' equity of $9.1 million. Its current ratio was 5.15. In the latest quarter (ended June 30, 2026) total assets were $6.9 million and equity $5.1 million.
Related: KRSA income statement, KRSA cash flow statement, KRSA key metrics. See the KRSA stock overview for the latest quote and news.
KRSA balance sheet FAQ
What are Korsana Biosciences's total assets?
Korsana Biosciences reported total assets of $10.0 million at the end of fiscal 2025 (December 31, 2025), compared with $9.6 million a year earlier.
How much cash does Korsana Biosciences have?
Korsana Biosciences held $3.2 million in cash and short-term investments at the end of fiscal 2025.
What is Korsana Biosciences's book value?
Korsana Biosciences's shareholders' equity (book value) was $9.1 million at the end of fiscal 2025.
What is Korsana Biosciences's current ratio?
Korsana Biosciences had current assets of $4.6 million and current liabilities of $0.9 million, a current ratio of 5.15 (it can cover its short-term obligations).